We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Polarean Imaging Plc | LSE:POLX | London | Ordinary Share | GB00BF3DT583 | ORD GBP0.00037 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.75 | 3.70 | 3.80 | 3.75 | 3.75 | 3.75 | 257,014 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 1.03M | -13.91M | -0.0644 | -0.58 | 8.09M |
Date | Subject | Author | Discuss |
---|---|---|---|
29/2/2024 07:51 | And current runway extended | moontheloon | |
29/2/2024 07:49 | 10p plus any funding. | moontheloon | |
29/2/2024 07:43 | The bigger problem is the continued slow commercial take-up. | nigelpm | |
29/2/2024 07:42 | 5p would be very generous. Not impossible but I'd think highly unlikely. The problem is the gap in funding and of course dilution to existing shareholders. | nigelpm | |
29/2/2024 07:40 | Strategic investors committed funding, funding from UK government. Additional few millions quid required from Investors. Im guessing the board will invest along with a few new Institutions. What price ? imho 5-10p | john henry | |
29/2/2024 07:38 | Expect the fund raise to come soon then at what price 3p maybe? Plenty of jam tomorrow or in a few years as it stands but shareholders will get stuffed with the fun raise | bones698 | |
29/2/2024 07:36 | The Company is exploring the appropriate financing options, with an anticipated launch in Q2-2024o Assuming a minimum financing of $10m, NUKEM Isotopes intends to commit $2.5m and Bracco intends to commit $2.0m to a prospective fundraise in the futureo The Company has obtained advanced assurance from His Majesty's Revenue & Customs (HMRC) to confirm £2.5m ($3.1m) of Enterprise Investment Scheme availability | babbler | |
29/2/2024 07:31 | 2.5m free funding from government. Wowsers. Nigel will hastily try to keep this down while I slithers from under his rock and in . Well done holders. Now breath | moontheloon | |
29/2/2024 07:26 | You're joking right? It's an absolute mess and that's before we look at the new targets. | nigelpm | |
29/2/2024 07:25 | At least they have a plan too!! Not sure what the market will do to it on the open bell | bloomberg2 | |
29/2/2024 07:18 | Wrong. 7.6 million dollars will be available. Excellent news, market will react very positively today! | sandy12345 | |
29/2/2024 07:14 | Want to raise 10m but only have 4.5m commited. Ouch. | nigelpm | |
23/2/2024 22:58 | Donegal1997 agree it is a binary bet and why I haven't topped up since I advised against moontheloon's advice to pile in and I would repeat that advice to any new investors. I am waiting to see if something materialises to rerate the shares before a fund raise and if not whether to top up either in a fund raise or after. | pj84 | |
23/2/2024 22:10 | I'm not convinced it's binary at all. Very small chance of a big return but high chance of a wipe out | nigelpm | |
23/2/2024 21:20 | Saietta a case study about what can happen when you burn through cash without commercial progress. Approaching crunch time for Polarean also. Binary bet at this point. | donegal1997 | |
23/2/2024 19:31 | W T Tutte thanks for posting the link, whilst it is only a phase 1 trial with just 6 patients it looks like it should read out very quickly by Apr 24. If the Hyperpolarized Xe 129 MRI Ventilation Imaging is able to show a significant difference in benefit between the 3 delivery methods it will help to demonstrate the benefit. | pj84 | |
23/2/2024 18:00 | Gold - "as it currently stands" was the key bit of what I said. No-one will allow current set up to continue - cash burn of c.$1m a month if they are putting fresh money in. | nigelpm | |
23/2/2024 16:48 | Polx 6.0p Nigelpm, The technology and the ability to scan chest area in such detail will prompt funding and the CEO in an interview has said he is confident of funding of Polarean in the near/medium term . It is just beyond understanding why Polarean directors have made no effort to sell into the UK or allow Philips exclusive rights here. They Polarean could sell such rights. On the Linkedin page they show medical equipment conference for Arab states and they have made no efforts there. Obsession with USA and how intelligent they are over and above everywhere else. There will be funding and the Chairman should be asked to leave. | goldbutler | |
23/2/2024 14:58 | Don't see why anyone would fund this as it currently stands. | nigelpm | |
23/2/2024 14:52 | No deals and no clisomf of the funding gap. Get ready for the surprise or not a surprise fund raise at a discount. The lack of deals considering how small they usually are is concerning and the share price isnrefelctimg the lack of progress. Meanwhile losses are mounting up and cash fast running out with no sight of break even for years. Left fund raising far too late and pis will pay the price | bones698 | |
23/2/2024 13:03 | But still no further commercial news. | nigelpm | |
23/2/2024 10:55 | Right I got end of stick in understanding I presumed they were testing the aerosol delivery for best reaction in lung using xenoview but didn't understand that once the optimum method located would be used in conjuction with xenoview ongoing. If so great. And maybe another potential suitor. Who knows. As much as i feel they have the issue in hand I do crave the security of funding news. But milestone wise prior I think the tech and usage is expanding further than we imagined. Multi use unique tech with no radiation limitations is very impressive. | moontheloon | |
23/2/2024 09:57 | I think the collaborator is the interesting bit. Aerogen is a world leader in acute care aerosol drug delivery. This is only a Phase I but it should lead to further trials and Xenoview will be used as a primary endpoint. This is actually quite a big deal and with in time and with success it should come with a slug of revenue. Also the fact that the FDA is prepared to accept output from Polarean as a primary outcome measure in a clinical trial is also a significant step. | w t tutte | |
23/2/2024 08:35 | Thanks tutte. University of Virginia... without checking... an existing trialist? Sounds a great idea..any trial that desires increased real clarity about lung function its got to involve polarean | moontheloon |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions